Format

Send to

Choose Destination
Infect Agent Cancer. 2013 Jun 12;8(1):22. doi: 10.1186/1750-9378-8-22.

Answering human papillomavirus vaccine concerns; a matter of science and time.

Author information

1
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria 3010, Australia. david.hawkes@florey.edu.au.

Abstract

Since the introduction of the HPV vaccine, questions have been asked about its efficacy in preventing cancer linked with HPV. Concerns about the HPV vaccine safety profile have also been raised. This paper highlights the rapidly growing body of evidence (including clinical trials and post-marketing surveillance) illustrating both the safety of the HPV vaccine, through a detailed investigation of reported adverse events, and its efficacy in reducing both HPV infections rates and the resulting drop in cervical lesions, which have been demonstrated to be good predictors of cervical cancer risk.

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center